Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...

This partnership brings together Remidio’s Medios DR AI for automated DR detection and RetinaRisk’s personalised risk ...

Dr. Michael Kapusta, MD, FRSCS, Ophthalmologist, talks about advanced (proliferative) diabetic retinopathy and pars plana ...

With vision loss due to diabetes emerging as one of the most serious yet overlooked complications in India, Firstpost brings ...

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Diabetic retinopathy (DR), a serious eye condition caused by damage to the blood vessels in the retina—the light-sensitive tissue at the back of the eye—is a ma ...

The global Diabetic Retinopathy Market is valued at USD 9.1 Billion in 2024 and is projected to reach a value of USD 15.1 ...

Diabetes affects more than 101 million people in India today. The number is estimated to reach 125 million by the year 2045.

Dr. Mohan’s Diabetes Specialities Centre (DMDSC) on Tuesday launched an AI-driven software to detect diabetic retinopathy at its Thanjavur Centre ...

Diabetic retinopathy affects 30 lakh Indians and can lead to vision loss. Advanced therapies include costly injections ...

Regeneron Pharmaceuticals ( NASDAQ: REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics license application ( (sBLA)) for Eylea HD injection, 8 mg, to treat macular ...

India holds the unenviable position of being home to the world’s largest diabetic population, with nearly 100 million ...